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Abstract
Since 1998, Bluetongue virus (BTV)-serotypes 1, 2, 4, 9, and 16 have invaded European countries around the Mediterranean
Basin. In 2006, a huge BT outbreak started after incursion of BTV serotype 8 (BTV8) in North-Western Europe. IN 2008, BTV6
and BTV11 were reported in the Netherlands and Germany, and in Belgium, respectively. In addition, Toggenburg orbivirus
(TOV) was detected in 2008 in Swiss goats, which was recognized as a new serotype of BTV (BTV25). The (re-)emergency of
BTV serotypes needs a rapid response to supply effective vaccines. Reverse genetics has been developed for BTV1 and more
recently also for BTV6. This latter strain, BTV6/net08, is closely related to live-attenuated vaccine for serotype 6 as
determined by full genome sequencing. Here, we used this strain as backbone and exchanged segment 2 and 6,
respectively Seg-2 (VP2) and Seg-6 (VP5), for those of BTV serotype 1 and 8 using reverse genetics. These so-called
‘serotyped’ vaccine viruses, as mono-serotype and multi-serotype vaccine, were compared for their protective capacity in
sheep. In general, all vaccinated animals developed a neutralizing antibody response against their respective serotype. After
challenge at three weeks post vaccination with cell-passaged, virulent BTV8/net07 (BTV8/net07/e1/bhkp3) the vaccinated
animals showed nearly no clinical reaction. Even more, challenge virus could not be detected, and seroconversion or
boostering after challenge was negligible. These data demonstrate that all sheep were protected from a challenge with
BTV8/net07, since sheep of the control group showed viremia, seroconversion and clinical signs that are specific for
Bluetongue. The high level of cross-protection is discussed.
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Introduction
Bluetongue virus (BTV) belongs to the family Reoviridae, genus
Orbivirus [1]. BTV transmission between ruminants, including
cattle, sheep, and goats, occurs in majority by bites of species of
Culicoides. Bluetongue (BT) is listed as a ‘notifiable disease’ by the
Office International des Epizooties (OIE) [2] causing severe
hemorrhagic disease with fever, lameness, coronitis, swelling of the
head (particularly the lips and tongue) and death. Twenty-four
BTV serotypes have been recognized as defined by cross-
neutralization assays, and recent BTV isolates are considered as
serotype 25 and 26, which was partially based on sequence data
[3,4].
The genome of BTV consists of ten linear double-stranded
RNA genome segments Seg-1 to Seg-10 encoding structural
proteins VP1 to VP7, nonstructural proteins, NS1, NS2 and NS3/
NS3a, for reviews see [5,6], and the recently discovered
nonstructural protein NS4 [7,8]. The virus particle composes
three shells of proteins, the inner shell consists of VP3 encoded by
Seg-3, the middle shell consists of VP7 encoded by Seg-7, and the
outer shell is formed by VP2 (Seg-2) and VP5 (Seg-6). The BTV
particle further contains three enzymatic proteins, VP1 (Seg-1),
VP4 (Seg-4) and VP6 (Seg-9), and one copy of each of the ten
genome segments Seg-1 to Seg-10 in the inner shell. The
nonstructural proteins NS1 (Seg-5), NS2 (Seg-8), NS3/NS3a
(Seg-10), and NS4 (Seg-9) are not part of the BTV particle.
Since 1998, BTV serotypes 1, 2, 4, 9, and 16 have invaded
European countries around the Mediterranean Basin. In 2006, a
huge BT outbreak started after incursion of BTV serotype 8 (IAH
collection nr. BTV-8 NET2006/04) [9] in N-W Europe [10].
More recently, BTV serotypes 6 and 11 were reported in N-W
Europe in 2008 [11,12,13,14]. Both BTV strains are closely
related to modified-live vaccine strains for their respective
serotypes [13,15]. In the same time period, an unknown orbivirus
named Toggenburg orbivirus (TOV or BTV25) was discovered in
Swiss goats [3].
Because of the repeated incursion of different serotypes there is
a need for vaccines which can be applied as soon as these are
available. The vaccination campaign for BTV serotype 8 (BTV8)
in the northern part of Europe was launched in 2008, two years
after the outbreak has started and after the devastating year 2007.
Further, by the incursion or discovery of new serotypes, like BTV
serotypes 25 and 26, it is evident that a rapid response to supply
vaccines of desired serotypes is needed.
One way to address this problem, is by use of the recently
developed reverse genetics system as described for BTV1 [16],
BTV6 [17], and BTV8 [7,17]. The reverse genetics system was
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e44619
used to genetically modify BTV [7,17,18,19] and to generate
reassortants [20].
Here, we used reverse genetics for vaccine-related BTV6/net08
[14] to exchange the outer shell for that of serotype 1 or 8 resulting
in so-called ‘serotyped’ vaccine viruses. These vaccines, used as
mono- or as multi-serotype vaccine, are completely protective for a
challenge with virulent BTV8.
Materials and Methods
Cell lines and virus
BSR cells (a clone of BHK-21 cells [21]) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) con-
taining 5% fetal bovine serum (FBS), 100 IU/ml penicillin,
100 mg/ml streptomycin and 2,5 ug/ml Amphotericin B.
All virus stocks were obtained by infection of BSR cells at low
multiplicity of infection (MOI) and harvested after 100%
cytopathic effect (CPE) was observed. Virus titers were determined
by endpoint dilution and expressed as plaque forming units per ml
(pfu/ml). Virus stocks were stored at 280uC.
Rescue of BTVs by transfection of plasmid-derived RNA
transcripts to mammalian cells
Transfection experiments with T7-derived RNA transcripts
from linearized plasmids were performed as previously described
for rgBTV1, 6 and 8 [17]. Briefly, monolayers of 105 BSR cells per
2 cm2 were transfected with 600 ng equimolar amounts of RNA of
BTV segments encoding VP1, VP3, VP4, NS1, VP6, NS2. In
total, 600 ng RNA was transfected using 1 mg lipofectamineTM
2000 (1:2.5; 1 mg/ml Invitrogen) in Opti-MEMH I Reduced
Serum Medium according to manufacturer’s conditions. Eighteen
to twenty hours post transfection, monolayers were transfected
again with 600 ng equimolar amounts of ten BTV RNA segments.
For serotyped BTV6 with the outer shell of BTV1 or 8, T7-
derived RNA transcripts of Seg-2 and Seg-6 from serotype 1 or 8
were added to complete the set of ten RNA transcripts. At 4 hrs
post transfection, the transfection mix was replaced with 1 ml
DMEM supplemented with 5% FBS. Supernatants were harvested
from monolayers developing cytopathogenic effect (CPE) at 48 hrs
after the second transfection. BTV-specific CPE was confirmed by
immunostaining of fixed monolayers with monoclonal antibody
(Mab) produced by ATCC-CRL-1875 directed against VP7
according to standard procedures. Serotyped vaccine viruses with
the outer shell of BTV1 or BTV8 were named BTVac-1 and
BTVac-8, respectively. According to the names of these serotyped
vaccine viruses (BTVac-x, x indicates the originating serotype of
the outer shell proteins), previously rescued rgBTV6 [17] was here
renamed BTVac-6.
Growth curve of BTVac-6, BTVac-1 and BTVac-8 on BSR
cells
Confluent BSR-monolayers in M24-well plates were infected in
duplicate at a multiplicity of infection (MOI) of 0.1. After
attachment to cells for 1.5 h at 37uC, the medium was removed
and refreshed with 1 ml of DMEM with 5% FBS, 1% Penicillin/
Streptomycin/Fungizone and incubation was continued. At 24,
48, 72 and 96 h post infection (hpi), samples of the supernatants
were harvested and stored at 280uC. Virus titers were determined
by endpoint dilution on BSR cells. Therefore, BSR cells were
infected with tenfold dilutions of samples, and grown for 72 h.
Positive wells were detected by immunostaining with VP7-specific
Mab ATCC-CRL-1875. Virus titers were expressed as tissue
culture infective dose (10logTCID)50/ml.
Vaccination/challenge experiment with serotyped BTV
viruses
All experiments with live animals were performed under the
guidelines of the European Community (86/609) and were
approved by the Committee on the Ethics of Animal Experiments
of the Central Veterinary Institute (Permit Number: 2011-003).
Twenty female Blessumer sheep of 6–24 months old and free of
BTV and BTV-antibodies were commercially sourced from the
same flock of a Dutch farm. The sheep were randomly allocated to
five groups of four animals. Although it was intended to inject the
animals with 1 ml virus with a titer of 105 TCID50/ml, BTVac-6
appeared to have a much lower virus titer when the inoculum was
re-titrated afterwards. Therefore, on day 0 (0 dpi), four sheep were
intramuscularly (i.m.) vaccinated in the neck with either 1 ml of
101.4 TCID50/ml BTVac-6, 1 ml of 10
5 TCID50/ml BTVac-1 or
BTVac-8. The fourth group (CombiVac group) was vaccinated
i.m. with 1 ml in total consisting of 0.33.101.4 TCID50/ml
BTVac-6, 0.33.105 TCID50/ml BTVac-1 and 0.33.10
5 TCID50/
ml BTVac-8. The fifth group served as control group. EDTA-
blood samples were collected daily during the first week after
inoculation and every other day until challenge at day 21. Serum
samples were collected daily in the second week and every other
day in the first and third week after immunization. Animals in all
five groups were challenged with a total of 1 ml of 105 TCID50/ml
of BTV8/net07/e1/bhkp3 [17], here named BTV8/net07. Virus
was injected subcutaneously (s.c.) to sheep between the shoulder
blades left and right from the spinal cord. EDTA-blood samples
were collected daily during the first week after challenge and every
other day until the end of the experiment at 21 days post
challenge. Serum samples were collected daily in the second week
and every other day in the first and third week after challenge.
EDTA-blood samples were tested by the in-house panBTV-
PCRtest [22,23]. Serum samples were tested by blocking ELISA
(ID.VET) for the detection of BTV-specific antibodies in serum.
Body temperature was recorded daily and fever was defined as the
average temperature plus two times the standard deviation.
Clinical signs were daily recorded according to the clinical score
table for BTV8 animal trials (Table S1). Clinical signs were
quantified following challenge by an adapted clinical reaction
index (CRI) as described by Huismans [24]. A maximum score of
12 was given to the cumulative total of fever readings (a) as
described above from days 3 to 14 post challenge (dpc), a clinical
score (0–3) for each parameter according the clinical score table to
a maximum score of 27 (b). An additional 4 points were added to
the sum of a and b if death occurred within 14 dpi. The relative
reaction (RR) is the CRI of the test sheep expressed as a
percentage of that of the control. The percentage protection index
= 100– RR.
Serum neutralisation test (SNT)
SNT was performed according to the method of Haig [25] using
BTV1/bsrp3 (rgBTV1), BTV8/net07/e1/bhkp3 (BTV8/net07)
and BTV6/Net08/e1/bhkp3/bsrp2 (BTV6/Net08). Briefly, sera
were diluted (1:10–1:10,240) and titrated against 30–300 TCID50
of the abovementioned BTV strains for 1 h at 37uC. Then, 100 ml
of a BSR cell suspension (26105/ml) was added per well and, after
incubation for 6–7 days at 37uC, the wells were scored for
cytopathic effect (CPE). The titer of neutralising antibodies (nAb
titer) was determined as the dilution of serum giving a 50%
neutralisation endpoint. Samples with nAb titers of .10 were
considered positive.
‘‘Serotyped’’ BTVs Confer Full Protection in Sheep
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Seg-2 and Seg-6 specific PCR tests
Virus stocks and selected RNA samples of previously tested
EDTA-blood samples by the panBTV-PCR test were analysed
with in-house developed serotype specific real time PCR tests for
serotypes 1, 6, and 8 (Table 1, [14]) targeting Seg-2 (S2-
genotyping). Virus stocks of rescued BTVac-x vaccine viruses
were also tested for the presence of Seg-6 RNA with PCR tests
with primers that discriminate between Seg-6 of BTV1,26 or28,
respectively (Table 1).
Detection of vaccine virus and challenge virus
The Seg-10 amplicon as detected by the diagnostic panBTV-
PCR test [23] of samples taken on 7, 14 and 21 dpc were further
analysed to differentiate between Seg-10 RNA from BTV8 and
from BTVac-x (S10-genotyping). Note that Seg-10 RNA from all
BTVac vaccine viruses originates from BTV6/net08. From
samples that were tested positive by the panBTV-PCR test, 5 ml
amplicon was digested with BsoBI (specific for Seg-10 of BTVac-x)
or with ApaLI (specific for Seg-10 of BTV8/net07), see Fig. 1.
Digested amplicons were analysed on a 1.5% agarose gel to
discriminate between amplicons derived from Seg-10 from
BTVac-x vaccine viruses and from challenge virus BTV8/net07.
The detection limit of digested amplicon was ,16 ng (Fig. 1),
whereas 5 ng of undigested amplicon can be detected (not shown).
Results
Reassortants with the outer shell of different serotypes
Since rgBTV6 (here named BTVac-6) was proven to be
avirulent [14], we studied the possibilities of using this avirulent
BTVac-6 as virus backbone to generate ‘synthetic’ reassortants
with the outer shell originating from BTV1 or BTV8/net07.
Previously, Seg-2 and Seg-6 sequences of BTV1 (genbank
accession numbers FJ969721 and FJ969723) and of BTV8 were
successfully used to rescue BTV1 [16,17] and rgBTV8 [17]. Here,
T7-derived RNA transcripts of these two genome segments were
used to complete the set of ten RNA transcripts for the second
transfection. Transfection supernatants were collected after two
days, at which clear CPE was observed for ‘serotyped’ BTVac-1
and BTVac-8. After virus stocks were prepared on BSR cells (one
passage), viruses were characterized by S2-genotyping for serotype
1, 6 and 8 and by PCR with primers specific for the respective Seg-
6 of BTV1,26 or28. The presence of both Seg-2 and Seg-6 were
confirmed for the respective BTVac-x viruses (not shown).
Growth characteristics of BTVac-1, BTVac-6 and BTVac-8
on BSR cells
The originating BTVac-6 or rgBTV6 and ‘serotyped’ vaccine
viruses BTVac-1 and BTVac-8 were compared for growth on BSR
cells (Fig. 2). Initial virus titers at 6 hpi showed no increase and
was below the detection level of 1.8 log10TCID50/ml. At 24 hpi,
both BTVac-1 and BTVac-8 grew to slightly higher virus titers
(4.59 and 4.76 log10TCID50/ml) compared to 4.26 log
10TCID50/
ml for BTVac-6. Maximum virus titers for BTVac-1, BTVac-6
and BTVac-8 were reached after 48 hours (5.88, 5.14 and
5.6 log10TCID50/ml, respectively). The differences in virus titers
as measured at 48 hpi remained for 72 and 96 hpi. Apparently,
BTVac-1 and BTVac-8 seemed to grow to slightly higher titers on
BSR cells than the originating rgBTV6 (BTVac-6).
Table 1. Primers used for differential detection of genome segment Seg-2 (S2-genotyping) and Seg-6 of BTV serotype 1, 6, and 8.
namea sequence expected amplicon size (bp)
BTV1VP2/283-1F TTGTTGAAAGTACGAGACACAAGAG 175
BTV1VP2/457-1R GTATCAGCCTTCTTTGAATCGATT
BTV1.1VP2 probe CATCCACTGCACCCACTGGTCA
BTV6VP2/1757-5F AGGAACAGTCGGCTTATCAC 192
BTV6VP2/1948-5R TTCGCTAATGTGCTTCTCCAT
BTV6.5 VP2 probe TTGTCAGCTTTACGCAAACCCCG
BTV8VP2/1873-4F CGGAGACAGCGCAGTATGTA 225
BTV8VP2/2097-4R CCTCGGTAGTATCCCTCACG
BTV8.4 VP2 probe ACATACGATGCCYTCGGAGGATTCTG
BTV1S6F1 AGTGATCAATGCTTTAAGCGGG 831
BTV1S6R GTAAGTGTAAGTGCTTCCCGTC
BTV6S6F1 GTTAAAAAGATCCCCATGAT 490
BTV6S6R4 CGCTTTACAGAGCACCTTAT
BTV8S6F GTTAAAAAAGCGATCGCTTTCG 638
BTV8S6R4 GCCTCTTTTAACGCATCG
a. Primers were purchased with Eurogentec Benelux. Probes were purchased with TibMolBiol Berlin and are labeled with FAM at the 59-end, and with the black hole
quencher (BHQ) at the 39-end.
doi:10.1371/journal.pone.0044619.t001
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Vaccination/challenge experiment with serotyped BTV
viruses
Vaccinated sheep developed fever for one or more days between
6 and 11 dpv (Fig. 3A). The increased body temperature in sheep
of the BTVac-6 group was observed approximately one day later
than in the other vaccinated groups. Vaccinated sheep were tested
positive by the panBTV-PCR test from 3 dpi onwards (Fig. 3B),
except for one sheep in the BTVac-1 and in the BTVac-8 group,
which became positive for BTV RNA only after 11 dpv. This
corresponds with fever readings only on 11 dpv for these
particular animals. All animals remained PCR positive, except
for one animal in the BTVac-8 group, which is the same animal
with the delayed fever and delayed PCR-positivity. All animals
seroconverted for BTV VP7 antibodies between 7–9 dpv (Fig. 3C).
All vaccinated animals developed very mild clinical signs like
nasal/ocular discharge and/or upper airway distress (Fig. 3D).
Sheep in the CombiVAc group had the same very mild clinical
signs but for a longer period. All sheep of the control group
remained negative in PCR and ELISA (Fig. 3B–C). None of the
Figure. 1. S10-genotyping by restriction analysis. (A) Sequence comparison of Seg-10 amplicons of BTVac-6 and BTV8/net07. Positions and
orientations of primers and probe (bold, italics, underlined) are indicated by arrows [23]. The unique restriction sites of BsoBI (CYCGRG) en ApaLI
(GTGCAC) are double underlined. (B) Mixing experiment of different amounts (ng) of Seg-10 amplicon from BTV6- or BTV8 digested with BsoBI or
ApaLI and analysed by electrophoresis on a 1,5% agarose gel.
doi:10.1371/journal.pone.0044619.g001
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sheep showed fever and only very mild signs were observed.
(Fig. 3A and D).
After challenge with virulent BTV8/net07e1/bhkp3 [17],
nonvaccinated sheep of the control group developed mild to
moderate clinical signs of BT (Fig. 3D), except for one sheep which
showed no clinical signs at all. More severe clinical signs were
observed from 9 days post challenge (dpc) onwards. Two of the
animals were listless, showed local oedema and red mucous in the
mouth for several days. All sheep in the control group developed
fever between 6 and 11 dpc. All sheep became PCR-positive
between day 3–6 dpc and remained PCR-positive until the end of
the trial (21 dpc) (Fig. 3B). Sheep seroconverted by ELISA from
7 dpc onwards (Fig. 3C).
Sheep in all vaccinated groups did not develop fever after
challenge (Fig. 3A). Vaccinated sheep showed very mild clinical
signs and sheep vaccinated with the CombiVAc showed slightly
more clinical signs after challenge (Fig. 3D). Since sheep in this
group still showed clinical signs at challenge, it is unclear whether
this was solely due to the challenge, or an accumulation of clinical
signs caused by challenge and vaccination.
On 21 dpv, all sheep in the BTVac-1 group and the BTVac-6
group were tested positive for the respective S2-genotyping,
whereas S2-genotyping was negative for serotypes not used for
vaccination (Table 2). For the BTVac-8 group, three out of four
sheep were tested positive for serotype 8, and all four were
negative for both serotype 1 and 6. The fourth sheep was tested
positive at 11 dpv for serotype 8, which corresponds to the results
of the panBTV-PCR test for this particular animal (data not
shown). Three out of four sheep in the CombiVac group were
tested positive for serotype 1 and 8, whereas only one sheep was
positive for serotype 6 at 21 dpv. At 11 dpv, all sheep were tested
positive for both serotype 1 and 8, but not for serotype 6 (data not
shown). After challenge, results for vaccinated animals were very
similar to results as obtained on 21 dpv/0 dpc Table 2). For
serotype 1 and 6, two sheep in the CombiVac group were tested
positive by the respective S2-genotyping. For serotype 8, three
sheep were positive by S2-genotyping for serotype 8 in both the
CombiVac group and the BTVac-8 group. However, since Seg-2
is the same for BTVac-8 and BTV8/net07, there is no
discrimination by S2-genotyping between vaccine virus and
challenge virus in these groups. Thus, no conclusion can be
drawn about viremia of BTV8/net07 in the BTVac-8 group and
the CombiVac group.
Sheep were not tested by S10-genotyping prior to challenge
with BTV8/net07. After challenge, samples of vaccinated sheep
on 7, 11 and 14 dpc were tested positive for S10-genotyping for
BTVac-x viruses, whereas all were negative for BTV8/net07
(Table 2). These results confirmed the findings by S2-genotyping
and indicates that challenge virus BTV8/net07 was not replicating
in all vaccinated groups. As expected, S10-genotyping of samples
from the control group of all three tested days after challenge were
positive for BTV8/net07 and negative for Seg-10 of BTVac-x
viruses.
The sensitivity of this test was determined by a mixing
experiment of defined amplicon material from BTV6 and 8
(Fig. 1). It was shown that at least 16 ng of digested amplicon
could be detected. The detection limit for undigested material was
approximately 5 ng of amplicon DNA (data not shown) and
Figure 2. Growth characteristics of BTVac-1, BTVac-6 and BTVac-8 on BSR cells. Virus was infected on confluent monolayers of BSR cells
grown in 2 cm2 wells with an MOI of 0.1. Total virus titers were determined at 0, 6, 24, 48, 72 and 96 hours post infection and expressed as tissue
culture infective dose (log10TCID50/ml).
doi:10.1371/journal.pone.0044619.g002
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Figure 3. Vaccination/challenge experiment with serotyped BTV viruses. On day 0 (0 dpi), four sheep were intramuscularly (i.m.) vaccinated
in the neck with 1 ml of 105 TCID50/ml BTVac-1, 1 ml of 10
1.4 TCID50/ml BTVac-6, or 1 ml of 10
5 TCID50/ml BTVac-8. A fourth group was vaccinated
‘‘Serotyped’’ BTVs Confer Full Protection in Sheep
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corresponds with a Cp signal of 31–33 in the panBTV-PCR test.
In conclusion, complete digestion of amplicon with the BTV6-
specific restriction enzyme confirmed the absence of undigested
amplicon, and consequently the absence of challenge virus BTV8/
net07.
Serotype specific neutralizing antibody (nAb) titer in the
different groups of sheep were determined by SNT with different
BTV serotypes (Table 3). Sheep vaccinated with BTVac-1
developed nAb titers (1:80 to 1:3,840) against BTV1 on 21 dpv,
whereas no nAb titers (,10 to 15) were found for BTV6 and very
low nAb titers (15 to 20) against BTV8. One sheep in this group
(4908) developed a significantly higher nAb titer (480) against
BTV8. On 42 dpv/21 dpc, nAb titers against BTV1 were
between 1:10 and 1:960, whereas titers for BTV6 were very low
(1:10 to 1:30). No significant increase of nAb titers against BTV8
was found in individual sheep after challenge, although a slightly
increase of nAb titers against BTV8 could be suggested. All sheep
in the BTVac-6 group developed significant nAb titers (1:160 to
1:640) on 21 dpv/0 dpc against BTV6, whereas very low nAb
titers (1:10 to 1:20) were measured for BTV1. nAb titers against
BTV8 varied between 1:40 and 1:320. On 42 dpv/21 dpc, low
nAb titers against serotypes 6 and 8 were measured (1:40 to 1:160),
and no nAb titers (,10) were detected against BTV1. All sheep
vaccinated with BTVac-8 group developed significant nAb titers
(1:480 to 1:2,560) against serotype 8 on 21 dpv, whereas no nAb
titers (,10 to 1:15) against serotypes 1 and 6 could be measured.
On 42 dpv/21 dpc, nAb titers were similar as before challenge
and varied between 1:80 to 1:2,560 for serotype 8, and not
detectable to very low (,20) for serotypes 1 and 6. In the
CombiVac group, nAb titers were measured on 21 dpv against
BTV1 (1:20 to 1:1,280) and BTV8 (1:160 to 1:5,120), but were not
detectable (,10 to 1:15) for BTV6. On 42 dpv/21 dpc, nAb titers
against BTV1 (1:320 to 1:1,280) and BTV8 (1:160 to 1:1,280)
were measured. For serotype 6, two out of four animals had
developed a nAbs titer against BTV6 (sheep 4913 and 4915).
These sheep were also positive by S2-genotyping for serotype 6
(data not shown). Sheep in the control group had no nAbs titers
prior to challenge with BTV8/net07. On 21 dpc, nAb titers for
BTV8 ranged from 1:960 to 1:3,840, whereas no nAb titer was
measured against serotypes 1, and 6, except for sheep 4917 (nAb
titer of 1:160 against BTV1).
After challenge, clinical scores of individual sheep were
calculated as clinical score index (CRI) (Table 3). Sheep of the
control group had a mean CRI of 861.58. Sheep in all vaccinated
groups showed a strong reduction of the CRI, although some mild
clinical signs were observed. The sheep in all vaccinated groups
showed a strong reduction in CRI although some mild clinical
signs were observed. Means CRI’s varied from 0.560.29 for
BTVac-1 and BTVac-6, 1.2560.75 for BTVac-8 and 1.7560.63
for the CombiVac group. Mean protection indices varied from
78% (CombiVac), and 84% (BTVac-8) to 94% for both BTVac-1
and BTVac-6.
Summarizing, BTVac-x vaccine viruses are protective in sheep
on three weeks after a single vaccination. Vaccination results in a
very strong reduction of clinical disease and completely blocks
viremia of virulent BTV8/net07 in sheep.
Conclusions and Discussion
The incursion of bluetongue virus serotype 8 (BTV8) in North-
Western Europe was firstly detected in the Netherlands in August
2006, and has resulted in one of the largest recorded BT
outbreaks. The threat of (re)emergence of a BTV serotype needs a
quick response to supply effective vaccines. There is a long record
of development and application of inactivated and live-attenuated
or modified-live BT vaccines, which both have advantages and
disadvantages [26,27,28]. Further, experimental vaccines have
been developed by different approaches, reviewed in Noad and
Roy [29]. Recently, reverse genetics was developed for BTV1
[16], BTV1 and BTV8 [7] and BTV1, BTV6 and BTV8 [17]
which can be used to further explore the knowledge of BTV and
improve current BT vaccines.
Vaccine-related BTV6/net08 has appeared to be avirulent in
the field and by experimental infection of different ruminant
i.m. with 1 ml in total consisting of 0.33.105 TCID50/ml BTVac-1, 0.33.10
1.4 TCID50/ml BTVac-6 and BTVac-8. On 21 dpv (arrow), all sheep, including the
control group were challenged subcutaneously (s.c.) with 1 ml of 105 TCID50/ml of BTV8/net07/e1/bhkp3. (A) body temperatures (mean values per
group; lines) were recorded daily. (B) BTV was determined by the panBTV-PCR test (mean values per group). (C) BTV-VP7 directed antibodies in serum
samples were detected with the panBTV blocking ELISA. The mean blocking percentage per group was displayed as 100-value (sample). (D) Clinical
scores were observed daily and displayed as total scores per group (bars per group).
doi:10.1371/journal.pone.0044619.g003
Table 2. Genotyping results from vaccinated and challenged animals with serotype specific PCR tests on Seg-2 (S2-genotyping)
and restriction enzyme analysis of amplicons of the panBTV-PCR test (S10-genotyping).
Group (n=4)
S2-genotyping (number of positive
animals)a S10–genotypingb
11 dpv 21 dpv 14 dpc 7 dpc 11 dpc 14 dpc
Serotype 1 6 8 1 6 8 1 6 8 BT Vac-x BTV8 BT Vac-x BTV8 BT Vac-x BTV8
BTVac-1 1 4 0 0 4 0 0 4 0 0 + + +
BTVac-6 6 0 4 0 0 4 0 0 4 0 + + +
BTVac-8 8 0 0 4 0 0 3 0 0 3 + + +
CombiVac 1, 6, 8 4 0 4 3 1 3 2 2 3 + + +
Control 8 0 0 0 0 0 0 0 0 4 + + +
a. S2-genotyping was based on a serotype specific PCR-test with specific primer sets listed in table 1 [14].
b. S10-genotyping was based on the panBTV-PCR test used for diagnostic purposes [23]. The amplicon was digested with specific restriction enzymes and analyzed on
an agarose gel, see materials and methods.
doi:10.1371/journal.pone.0044619.t002
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species [30,31]. Further, BTV6 regenerated by reverse genetics
rgBTV6 (in this study named BTVac-6) was indeed avirulent [17].
Therefore, we selected this avirulent BTV strain as genetic
backbone for vaccine development and changed the serotype by
exchange of Seg-2 and Seg-6 for these of BTV1 and BTV8. Seg-2
and Seg-6 encode for the outer shell proteins VP2 and VP5. In
particular VP2 induces a protective humoral neutralising immune
response, which is highly specific for the respective serotype (see
references in: [29]). By this method, BT vaccine for another
serotype can be made rapidly by exchange of two segments from
circulating or (re)emerging BTV serotypes.
The two outer capsid proteins VP2 and VP5 are responsible for
virus entry into the host cells. In mammalian cells BTV entry
proceeds via virus attachment to the cell, followed by endocytosis
and release of a transcriptionally active core particle into the
cytoplasm [32,33,34,35,36]. The structural features of VP2
(propeller-like spike) and VP5 (globular) of the outer capsid
correlate with their biological roles in virus entry into the cells [6].
The most exposed BTV protein VP2 is the highly variable protein
among BTV serotypes and is the determinant of the serotype.
Antibodies raised against VP2 neutralise virus infectivity support-
ing the fact that VP2 is the cellular receptor binding protein of the
virus [37]. The globular outer capsid protein VP5 is likely to be the
membrane penetration protein. VP5 protein shares certain
secondary structural features with the fusion proteins of enveloped
viruses, indicating that it may play a role in virus penetration
activity [38]. The outer shell proteins VP2 and VP5 of BTV6 were
exchanged with that of BTV1 or BTV8 and therefore this might
influence some of the functions mentioned above like infectivity
and/or virulence.
In this study two ‘serotyped’ BTVs were generated by
completing the backbone of BTV6 (eight segments) with Seg-2
and Seg-6 from BTV1 or BTV8 resulting in BTVac-1 and
BTVac-8, respectively. In line with this, rgBTV6 [17] was re-
named BTVac-6 in this study. Rescued vaccine viruses (BTVac-x;
x presents the serotype) were characterized and compared.
Still, initial virus titres were comparable (within 0.5 log10
TCID50/ml) at 24 hpi for the generated BTVac-x viruses. The
Table 3. nAb titres by serum neutralizing tests (SNTs), clinical reaction indexes (CRIs) and the percentage of protection.
Group
Animal
number SNT titres (day) against BTV1, BTV6 or BTV8
a
CRIb % protectionc
21 (0 dpc) 42 (21 dpc)
BTV1 BTV6 BTV8 BTV1 BTV6 BTV8
BTVac-1 4905 80 15 15 10 20 20 0 100
4906 120 ,10 15 30 10 20 0 100
4907 640 15 20 960 20 80 1 87.5
4908 3840 10 480 160 30 640 1 87.5
Mean 6 SE 0.560.29 93.863.6
BTVac-6d 4901 ,10 640 80 ,10 160 40 0 100
4902 10 640 320 ,10 80 120 1 87.5
4903 20 160 ,10 ,10 160 40 0 100
4904 10 320 40 ,10 40 40 1 87.5
Mean 6 SE 0.560.29 93.863.6
BTVac-8 4909 ,10 ,10 480 ,10 20 80 3 62.5
4910 ,10 ,10 480 ,10 10 480 2 75
4911 ,10 ,10 640 15 20 320 0 100
4912 ,10 10 2560 ,10 30 2560 0 100
Mean 6 SE 1.2560.75 84.469.4
CombiVace 4913 1280 15 160 1280 640 480 2 75
4914 20 ,10 960 320 10 1280 3 62.5
4915 20 15 640 480 320 160 2 75
4916 30 ,10 5120 480 ,10 1280 0 100
Mean 6 SE 1.7560.63 78.167.9
control 4917 ,10 ,10 ,10 ,10 15 1280 6 NA
4918 10 10 15 160 10 3840 9 NA
4919 ,10 ,10 ,10 ,10 ,10 2560 5 NA
4920 ,10 ,10 ,10 ,10 ,10 960 12 NA
Mean 6 SE 8.061.58
a. The respective serum neutralization titres were determined against 30–300 TCID50 of the indicated BTVs and expressed as the dilution of serum giving a 50%
neutralisation endpoint.
b. The clinical reaction index (CRI) was determined according to Huismans et al [24]. See also materials and methods.
c. The percentage of protection was determined as 100-RR, in which RR is the CRI of each sheep expressed as a percentage of that of the average control.
d. BTVac-6 was previously named rgBTV6 [17].
e. CombiVac is a combination of BTVac-1, BTVac-6, BTVac-8.
doi:10.1371/journal.pone.0044619.t003
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maximum titre of BTVac-1 was even slightly higher (0.2–1 log10
TCID50/ml) at all following time points (48, 72 and 96 hpi),
whereas the original BTVac-6 was the lowest at each of the
following time point (Fig. 2). Apparently, these outer shell proteins
fit well on the BTV6 core particle. Since the difference between
these BTVac-x viruses is limited to Seg-2 and Seg-6, it can be
concluded that the observed small growth advantage for the two
serotyped viruses is caused by VP2 and/or VP5. It is unknown
whether this small difference in virus replication in vitro also reflects
a difference in virus replication in vivo.
Unfortunately, a non-intended lower dose of BTVac-6 was used
for vaccination of sheep compared with respect to the ‘serotyped’
vaccine viruses BTVac-1 and BTVac-8. Although the sheep of the
BTVac-6 group were slightly delayed in developing fever and
PCR-positivity, all sheep seroconverted by ELISA between 7–
9 dpi (Fig. 3C) which was comparable to the other vaccinated
groups. This indicated that the lower dose of 1 ml of
101.4 TCID50/ml BTVac-6 is sufficient to vaccinate animals and
resulted in comparable seroconversion with respect to vaccination
with 1 ml of 105 TCID50/ml of BTVac-1 or BTVac-8. As a
consequence of the lower titre of the virus stock, the one-third
amount of BTVac-6 in the CombiVac group was also lower and
was much less than for the other two BTVac-x vaccine viruses.
Apparently, the amount of BTVac-6 in this combination was
limited, since BTVac-6 could not be detected in all vaccinated
sheep (Table 2). Further, two out of four sheep did not raise
significant nAb titres specific for serotype 6, and the two other
sheep showed only very low nAb titres for serotype 6 (Table 3).
From these data, however, it is not clear whether this is caused by
the limited amount of BTVac-6, negative interference by the
excess of other BTVac-x viruses, or by the slightly slower
replication rate of BTVac-6 as observed in vitro.
Besides fever, only very mild clinical signs (Fig. 3D) were
observed in vaccinated sheep, which was also seen in experimental
infections of BTV6/net08 and rgBTV6 (here named BTVac-6)
[14,17]. It can therefore be concluded that VP2 and VP5, of which
these originated from virulent BTV8/net07 in BTVac-8, are not
associated with virulence. Sheep in the CombiVac group showed
similar clinical signs but for a longer period of time. Likely, sheep
react stronger after vaccination with immunogenic different
viruses and/or needs more time to recover from vaccination.
For future research, this observation should have to be taken into
account in the light of combining BTVac-x vaccine viruses.
Sheep of the control group showed several days with fever after
challenge with BTV8/net07, whereas vaccinated sheep did not.
The control group had an average CRI of 8, whereas average
CRI’s of the vaccinated groups were ,2. This indicated that one
single vaccination clearly reduce clinical disease in sheep. Sheep in
the CombiVac group seemed to be a little less protected (Table 3),
but it is unclear whether the measured CRI’s after challenge are
caused by challenge virus, and thus are less protected by
CombiVac, or are the result of prolonged clinical reaction by
CombiVac vaccination, or are the sum of both.
No challenge virus was detected in vaccinated sheep, indicating
that a single vaccination completely blocks replication of challenge
virus. No seroconversion or booster of the humoral neutralising
immune response specific for serotype 8 was measured for
vaccinated sheep after challenge. This confirms the absence of
replication of the virulent challenge virus BTV8/net07.
Prior to challenge, vaccinated animals developed significant
nAb titres against the respective serotype and very low nAb titres
or none at all for the other serotypes. Still all vaccinated sheep,
irrespective of the used vaccine virus, were protected from
challenge with BTV8/net07, thus including the groups vaccinated
with BTVac-1 and BTVac-6. We suggest that cross-protection as
observed in this study is due to a nonspecific cell-mediated
immune response. Cross-protective immune response to BTV has
been described [39]. This cross-protective response involves VP2
and NS1 as major ovine CTL immunogens of which NS1 is cross-
protective and VP2-specific CTL responses are not [40].
A longer time period, e.g. four weeks or more, after vaccination
with live-attenuated vaccine will show serotype specific protection.
Anti-BTV CTL’s showing serotype cross-reactivity have been
demonstrated to peak between 7 and 21 days after infection
[40,41,42] and even extends to 66 days after multiple immuniza-
tion [40]. Still, the detected serotype specific nAb titre after
vaccination with BTVac-x viruses is very promising in the light of
long lasting protection for the respective serotypes, and can be
expected to be very similar as for live-attenuated vaccines.
The selected vaccine virus background BTVac-x is safe, by
which x represents the serotype of the outer shell proteins, even if
completed with outer shell proteins of virulent BTV8/net07
(Fig. 3). Apparently, no virulence markers are located on VP2 or
VP5 of BTV8/net07. Small differences in nAbs titres could be
caused by the lower dose (101.4 TCID50/ml) for BTVac-6 than for
the other vaccinated groups (105 TCID50/ml). Further, for
combination vaccines consisting of BTVac-x viruses, the amount
of each BTVac-x have to be comparable, since negative
interference between different BTVAc-x viruses could be expected
resulting in a less pronounced viremia and a lower level of nAbs
titres (Tables 2 and 3).
The quick generation of BTVac-x vaccine viruses by use of the
genetic backbone of vaccine-related BTV6/net08 can also be used
to generate safe BTVac-x vaccine virus for other serotypes.
Serotyping of rgBTV6 (BTVac-6) presented here for serotypes 1
and 8 is promising for serotyping for other BTV serotypes. Indeed,
‘serotyping’ can be extended for other serotypes but is not
unlimited. We were able to ‘serotype’ for TOV, the proposed 25th
serotype [3], and a few others but not for all BTV serotypes [43].
In conclusion, these results show the strategy to develop faster BT
vaccines for desired BTV serotypes. However, issues regarding
compatibility of Seg-2 and Seg-6 from other serotypes need to be
addressed, in particular with respect to protein-protein interactions
between these outer shell proteins and the core of BTV6/net08.
Since both live-attenuated and inactivated vaccines currently
have a history of safety issues, improvement of safety is an
important issue. Recently, protection against BTV8 by replication-
defective BTV1 with VP2 of BTV8 was shown [44]. These data
indicate that VP2 of the respective serotype is sufficient to induce
protection, although nonhomologous challenge was not included
in this study. Thus, serotype-independent protection could be
involved as observed for BTVac-x vaccine viruses in this study.
BTVac-x vaccine viruses can be easily generated and are effective
in the induction of serotype-specific nAbs as soon as 21 dpi after a
single vaccination. Most likely, these tested BTVac-x vaccine
viruses will be protective for their respective serotype, like it has
been observed for traditionally generated live-attenuated BT
vaccines.
Development of DIVA vaccines (DIVA: Differentiating Infected
from Vaccinated Animals) is of significant importance to control
Bluetongue. BTVac-x vaccines induce a complete immune
response against the respective serotypes. Consequently, animals
vaccinated with BTVac-x vaccines cannot be distinguished by
serological testing from animals infected by the respective BTV
serotype. In 2008, BTV1 and BTV6 were detected by genotyping
on Seg-10 in the infected and vaccinated ruminant population for
BTV8 [14]. This method is irrespective of the serotype, and
combines the high-throughput panBTV PCR assay [23] and
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sequencing of amplicons between the PCR-primer positions. Here,
we have improved this method for routine use to differentiate
between virulent BTV8 and BTVac-x vaccines. Note that all
BTVac-x vaccines have the same genetic background of BTV6,
and that field BT-viruses will be detected/identified by the high
genetic variation in Seg-10. Thus, BTVac-x vaccines in combi-
nation with genotyping on Seg-10 are DIVA-vaccines to detect
infectious animals in vaccinated populations.
The system of tailor-made vaccines by exchange of outer shell
proteins for those of other serotypes in a defined avirulent genetic
backbone offers more advantages, like fully defined genomes, and
similar growth characteristics in vivo and in vitro. Moreover, these
‘serotyped’ BTVac-x vaccine viruses share eight out of ten genome
segments, and consequently the chance on new undesired
(virulent) reassortants after mixing these, e.g. for multi-serotype
vaccines, is negligible. In addition, the proteins VP2 and VP5 that
differ between BTVac-x vaccine viruses do not harbor virulence
markers for the tested BTV serotypes. Further, due to the same
replication machinery, negative interference between BTVac-x
vaccine viruses after vaccination is reduced to a minimum,
although equal amounts of each BTVac-x virus seems to be
important as shown in this study. Finally, by the similar growth
characteristics in vitro of BTVac-x viruses, similar costs for virus
production of each BTVac-x virus could be expected. Noteworthy,
these BTVac-x viruses can be used as live-attenuated BT vaccine
or, in order to address safety issues, as inactivated BT vaccine.
Research is in progress to start ‘serotyping’ of BTV6/net08 for
other serotypes in order to develop virus stocks of more BTVac-x
viruses for vaccine production.
Supporting Information
Table S1 Clinical score table BTV animal trial. The clinical
signs described in this table were based on findings in the field [45]
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